Mevalonate kinase deficiency
|Mevalonate kinase deficiency|
|A patient with mevalonate kinase deficiency at the age of 21 months, displaying characteristic craniofacial features.|
|Classification and external resources|
Mevalonate kinase deficiency, also called mevalonic aciduria and hyper immunoglobin D syndrome is an autosomal recessive metabolic disorder that disrupts the biosynthesis of cholesterol and isoprenoids.
It is characterized by an elevated level of immunoglobin D in the blood.
The enzyme is involved in biosynthesis of cholesterols and isoprenoids. The enzyme is necessary for the conversion of mevalonate to mevalonate-5-phosphate in the presence of Mg2+ [Harper’s biochemistry manual]. Mevalonate kinase deficiency causes the accumulation of mevalonate in urine and hence the activity of the enzyme is again reduced Mevalonate kinase deficiency. It was first described as HIDS in 1984.
Mevalonate kinase deficiency is an example of loss-of-function mutation. There is a mutation in the gene which is coding for mevalonate kinase which is at 12q24 locus . There are almost 63 pathological sequence variations which is present throughout the 10 exons. The most common mutations are V377I, I268T, H20P/N and P167L. These mutations are present in 70% of the affected individuals . A person with HIDS has two HIDS-mutations only id the parents of the patients are carriers. The risk of a child of parents who are both carriers to get the disease is 25%. In half of the cases, the child of such parents will be a carrier of the mutation. But a child does not always get the inherited predisposition. The inheritance of genes is purely coincidental. So, either all the children ae unaffected or three-fourth are affected. If the affected individual has both the mutations and he marries an unaffected individual, then the children of the affected individuals won’t be ill but will act as carrier .
Immunoglobulin D (IgD) is a protein produced by a certain type of white blood cells. There are five classes of Immunoglobin like IgG, IgA and IgM, IgE and IgD. They play an important role in the immune system. The function of IgD is still unclear.
There is a relationship between MKD and the interleukin 1beta (IL-Iβ). There is an increased IL-1β secretion and mevalonate kinase deficiency in MKD is most likely mediated by defective protein prenylation (Prenylation refers to addition of hydrophobic residues to proteins) ] and non-sterol isoprenoids, such as farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP) are coupled to a target protein, which affects the activity and the cellular location. In a human monocytic MKD model it was found that the deficiency of GGPP leads to overproduction of IL-1β and defective prenylation of RhoA. This causes an increased level of Rac1 and PKB which was affecting the GTPases and B7-Glycoproteins. It was earlier found that Rac1/PI3K/PKB pathway had been linked to the pathogenesis of MKD. The inactivation of RhoA acts an inducer of IL-1β mRNA transcription independent of NLRP3- or caspase-1 activity. Due to defective RhoA there is a formation of defective mitochondria (elongated and instable) in the cell. If a defective mitochondria it is cleared in the cell by the mechanism of autophagia. But, in MKD the clearance of defective mitochondria from the cytosol is disrupted. As a result, the mitochondrial DNA starts accumulating in the cytosol which binds and activates NLRP3 which is responsible for the production of IL-1β. The activation can be direct or indirect. It can also be activated by reactive oxygen species (ROS). It is known that monocytes and macrophages also produce higher levels of tumor necrosis factor alpha (TNF-α), interleukin 6(IL-6) other than IL-Iβ  During the febrile (fever) attacks and during the attacks the C - reactive protein (CRP) also increases. . The CRP is released by liver which causes inflammation.
Mevalonate kinase deficiency causes an accumulation of mevalonic acid in the urine, resulting from insufficient activity of the enzyme mevalonate kinase (ATP:mevalonate 5-phosphotransferase; EC 188.8.131.52).
The disorder was first described in 1985.
Classified as an inborn error of metabolism, mevalonate kinase deficiency usually results in developmental delay, hypotonia, anemia, hepatosplenomegaly, various dysmorphic features, mental retardation, an overall failure to thrive and several other features.
There is no treatment for MKD. But, the inflammation and the other effects can be reduced to a certain extent.
- IL-1 targeting drugs can be used to reduce the effects of the disorder. Anakinra is antagonist to IL-1 receptors. Anakinra binds the IL-1 receptor, preventing the actions of both IL-1α and IL-1β, and it has been proved to reduce the clinical and biochemical inflammation in MKD. It can effectively decreases the frequency as well as the severity of inflammatory attacks when used on a daily basis. Disadvantages with the usage of this drug are occurrence of painful injection site reaction and as the drug is discontinued in the near future the febrile attacks start. (Examined in a 12-year-old patient).
- Canakinumab is a long acting monoclonal antibody which is directed against IL-1β has shown to be effective in reducing both frequency and severity in patients suffering from mild and severe MKD in case reports and observational case series. It reduces the physiological effects but the biochemical parameter still remain elevated (Galeotti et al. demonstrated that it is more effective than anakinra –considered 6 patients suffering from MKD).
- Anti-TNF therapy might be effective in MKD, but the effect is mostly partial and therapy failure and clinical deterioration have been described frequently in patients on infliximab or etanercept. A beneficial effect of human monoclonal anti-TNFα antibody adalimumab was seen in a small number of MKD patients.
- Most MKD patients are benefited by anti-IL-1 therapy. However, anti-IL-1-resistant disease may also occur. Example. tocilizumab (a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor). This drug is used when the patients are unresponsive towards Anakinra. (Shendi et al. treated a young woman in whom anakinra was ineffective with tocilizumab). It was found that it was effective in reducing the biochemical and clinical inflammation .Stoffels et al. observed reduction of frequency and severity of the inflammatory attacks, although after several months of treatment one of these two patients persistently showed mild inflammatory symptoms in the absence of biochemical inflammatory markers.
- A beneficial effect of hematopoietic stem cell transplantation can be used in severe mevalonate kinase deficiency conditions (Improvement of cerebral myelinisation on MRI after allogenic stem cell transplantation was observed in one girl). But, liver transplantation did not influence febrile attacks in this patient.
In the world less than 1 in 1.00.000 have HIDS . 200 individuals throughout the world do suffer from MVK.
- Online Mendelian Inheritance in Man (OMIM) 251170
- Mancini J, Philip N, Chabrol B, Divry P, Rolland MO, Pinsard N (May–Jun 1993). "Mevalonic aciduria in 3 siblings: a new recognizable metabolic encephalopathy". Pediatr. Neurol. 9 (3): 243–246. PMID 8352861. doi:10.1016/0887-8994(93)90095-T.
- Background information, HIDS.net, retrieved 28 August 2016
- Mulders-Manders, CM; Simon, A (2015). "Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?". Semin Immunopathol. 37: 371–6. PMC . PMID 25990874. doi:10.1007/s00281-015-0492-6.
- Bretón Martínez JR, Cánovas Martínez A, Casaña Pérez S, Escribá Alepuz J, Giménez Vázquez F (Oct 2007). "Mevalonic aciduria: report of two cases". J. Inherit. Metab. Dis. 30 (5): 829. PMID 17578678. doi:10.1007/s10545-007-0618-7.
- Berger R, Smit GP, Schierbeek H, Bijsterveld K, le Coultre R (Oct 1985). "Mevalonic aciduria: an inborn error of cholesterol biosynthesis?". Clin. Chim. Acta. 152 (1-2): 219–222. PMID 4053401. doi:10.1016/0009-8981(85)90195-0.
- Mulders-Manders CM, Simon A (2015). "Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?". Semin Immunopathol. 37: 371–6. PMC . PMID 25990874. doi:10.1007/s00281-015-0492-6.